Critical Contrast: Kinaxis (OTCMKTS:KXSCF) versus Avalon GloboCare (NASDAQ:CHGA)

Avalon GloboCare (NASDAQ:CHGA) and Kinaxis (OTCMKTS:KXSCF) are both technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Analyst Recommendations

This is a breakdown of recent recommendations for Avalon GloboCare and Kinaxis, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalon GloboCare	1	0	0	0	1.00
Kinaxis	0	0	4	0	3.00

Valuation and Earnings

This table compares Avalon GloboCare and Kinaxis”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalon GloboCare	$1.26 million	0.69	-$18.26 million	($13.80)	-0.06
Kinaxis	$548.03 million	7.49	$70.70 million	$3.20	47.40

Kinaxis has higher revenue and earnings than Avalon GloboCare. Avalon GloboCare is trading at a lower price-to-earnings ratio than Kinaxis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Avalon GloboCare and Kinaxis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avalon GloboCare	N/A	N/A	-53.69%
Kinaxis	14.35%	22.31%	12.48%

Institutional & Insider Ownership

1.4% of Avalon GloboCare shares are owned by institutional investors. 16.8% of Avalon GloboCare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Kinaxis beats Avalon GloboCare on 10 of the 12 factors compared between the two stocks.

About Avalon GloboCare

Avalon GloboCare Corp. is a biotechnology company historically focused on developing cell-based technologies, regenerative medicine applications and precision-medicine solutions. Its work has included research and development involving cellular therapies, immunotherapy and other platforms intended to support the treatment of serious diseases. The company’s reported activities have included the development of CAR-T and other cell-therapy approaches, exosome-related technologies, and diagnostic and biobanking services.

About Kinaxis

Kinaxis Inc. is a Canadian software company that develops cloud-based supply chain planning and management solutions. Its platform, Kinaxis Maestro, helps organizations coordinate planning across their supply chains and respond to changes in demand, supply and operations. Maestro supports activities such as demand and supply planning, inventory management, scenario analysis and sales and operations planning. The company also provides implementation, training and support services to help customers use its software.